Get the Stockscreener App
2.59
3.36%
-0.09
After Hours:
2.60
0.01
+0.39%
Pepgen Inc stock is traded at $2.59, with a volume of 513.04K.
It is down -3.36% in the last 24 hours and down -24.38% over the past month.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
See More
Previous Close:
$2.68
Open:
$2.68
24h Volume:
513.04K
Relative Volume:
0.56
Market Cap:
$179.38M
Revenue:
-
Net Income/Loss:
$-77.22M
P/E Ratio:
-1.4772
EPS:
-1.7533
Net Cash Flow:
$-77.27M
1W Performance:
-9.12%
1M Performance:
-24.38%
6M Performance:
-46.93%
1Y Performance:
-55.95%
1-Day Range:
$2.585
$2.72
1-Week Range:
$2.585
$3.03
52-Week Range:
$1.31
$7.80
Pepgen Inc Stock (PEPG) Company Profile
Name
Pepgen Inc
Sector
Industry
Phone
703-456-8000
Address
1 MARINA PARK DRIVE, SUITE 900, BOSTON
Compare PEPG vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
2.59 | 179.38M | 0 | -77.22M | -77.27M | -1.7533 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-25 | Initiated | Guggenheim | Buy |
| Dec-16-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-31-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-21-22 | Initiated | H.C. Wainwright | Buy |
Pepgen Inc Stock (PEPG) Latest News
PepGen presents ongoing DM1 research findings at NMSG Meeting - Traders Union
PepGen Ltd (NYSE: PEPG) Share Price, PEPG Stock News, PEPG Share Price & Updates - kalkine.ca
PEPG Should I Buy - Intellectia AI
PepGen Inc.Common Stock (Nasdaq:PEPG) Detailed Stock Data - The Chronicle-Journal
PepGen schedules oral and poster DM1 research at NMSG and WMS2026 conferences - Traders Union
PepGen Inc (PEPG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PEPG Q2 2026 Earnings: Narrower Loss Beats Estimates, Shares Rise 4.35%Post-Announcement Reaction - vinanet.vn
PEPG Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 3.34% BounceDownward Estimate Revision - vinanet.vn
PepGen (PEPG) Edges Higher to $3.08 as Shares Hold Narrow Trading RangeMerger Arbitrage - vinanet.vn
Investor Alert: Deadline Approaching to Join PepGen Inc. (PEPG) Class ActionContact Levi & Korsinsky - The National Law Review
PepGen (PEPG) Q2 2026 Results: EPS Comes in Above Forecast on the Day; Post-Earnings: Shares Close 3.46% Higher in the Current UpdateReturn On Equity - vinanet.vn
PepGen (PEPG) Earnings Reading: EPS Beats Its Estimate on the Day; Latest Reaction: The Stock Records a 0.96% Increase in the Latest ReadingCFO Commentary Report - careplusvn.com
PepGen (PEPG) Financial Update: The Bottom-Line Figure Beats Its Comparison on the Day; Trading Move - vinanet.vn
PepGen (PEPG) Financial Update: The Bottom-Line Figure Beats Its Comparison on the Day; Trading Move: Shares Finish 0.98% Higher on the DayShare Repurchase Impact - dars.gov.et
GSA Capital Partners LLP Makes New Investment in PepGen, Inc. $PEPG - MarketBeat
PEPG Q2 2026 Earnings: Narrower Loss Beats Estimates as Pipeline Progress ContinuesEBITDA Analysis - vinanet.vn
PepGen, Inc. (NASDAQ:PEPG) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
PepGen’s DM1 Bet Runs Into An FDA Hold And Dilution Fears - Finimize
PepGen Inc. (PEPG) Slips 1.17% to $2.94 as Biotech Stock Holds Above Key SupportUp Down Volume - vinanet.vn
Stifel Maintains PepGen(PEPG.US) With Buy Rating, Maintains Target Price $12 - Moomoo
PepGen (PEPG) Climbs 1.21% as Shares Approach Key $3.09 Resistance ZoneHigh Volume Stocks - vinanet.vn
Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation - Moomoo
PepGen identifies muscle weakness and myotonia as drivers of speech challenges in DM1 - Traders Union
HC Wainwright Has Positive Outlook of PepGen FY2027 Earnings - MarketBeat
Weekly Recap: 12.5/10 mg/kg dose escalation and Q4 2027 cash runway - TradingView
PepGen Inc. (PEPG) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of August 8, 2025 Deadline - The National Law Review
PepGen (NASDAQ:PEPG) Posts Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
PepGen Inc. Stock 12‑Month Price Target Cut to $10.19, Implies 323% Upside - TradingView
PepGen Inc (PEPG) Stock News Today - TradingKey
PepGenCash of $117.20 Mln as of June 30, 2 - Moomoo
PepGen Maintained at Buy as Analyst Cites Encouraging DM1 Safety/Efficacy Profile and Keeps $20 Price Target - TipRanks
H.C. Wainwright Maintains PepGen(PEPG.US) With Buy Rating, Maintains Target Price $20 - Moomoo
PepGen advances DM1 trial to highest dose cohort - Investing.com
PepGen Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Craig-Hallum Maintains PepGen(PEPG.US) With Buy Rating, Maintains Target Price $11 - moomoo.com
PepGen advances DM1 trial to highest dose cohort By Investing.com - Investing.com South Africa
PepGen Advances PGN-EDODM1 Trial and Strengthens Finances - TipRanks
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - biospace.com
PepGen Q2 net loss narrows as expenses fall - TradingView
PepGen Posts $17.8 Million Q2 Loss as Cash Reaches $117.2 Million - Quiver Quantitative
PepGen Inc. 1H 2026: Net loss $(35.6M), EPS $(0.51) — 10-Q Summary - TradingView
PGN-EDODM1 enters top dose group in new PepGen study - Traders Union
BRIEF-PepGen Q2 EPS USD -0.26 - TradingView
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review - Yahoo Finance
Class Action Filed Against PepGen Inc. (PEPG) Over Securities ViolationsContact Levi & Korsinsky Today - The National Law Review
PepGen Inc. (PEPG) Climbs 2.66% to $1.93 as Traders Eye Key Resistance at $2.03Revenue Growth Stocks - vinanet.vn
PepGen Inc expected to post a loss of 29 cents a shareEarnings Preview - TradingView
Shareholders of PepGen Should Contact Faruqi & Faruqi Before August 11, 2025 to Discuss Your RightsPEPG - TMX Newsfile
PEPG Q1 2026 Earnings: Narrower-than-Expected Loss Signals Cost Discipline Amid Pipeline AdvancementEPS Surprise History - careplusvn.com
PepGen: PGN-EDODM1 Multisystem Efficacy Potential Supports Buy Rating with Unchanged $20 Price Target - TipRanks
Pepgen Inc Stock (PEPG) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):